B

OSTON — The chemical arrived in September from a company in Ukraine, by way of a middleman in Portland, Maine. It was a whitish powder, and 10 grams — a bit more than two teaspoons’ worth — cost around $1,000.

That wasn’t bad for this business, and anyway, it was worth it. In 2015, this molecule had been shown to work against the single-cell parasite that causes visceral leishmaniasis, one form of a neglected tropical disease that kills an estimated 20,000 to 40,000 people a year. The chemical wasn’t perfect, though. It was unstable — so delicate that a hamster’s body broke it down before it could actually do its job.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.